Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PharmAkea Therapeutics
San Diego, California, United Statespharmakea.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PharmAkea Therapeutics developed small molecule inhibitors targeting key proteins involved in fibrotic diseases and cancer. Its lead asset, PAT‑1251 (a LOXL2 inhibitor), reached Phase II readiness for fibrotic disease and some cancers. Another program targeting autotaxin (PAT‑409) reached Phase I readiness before being sold to Blade Therapeutics. The company merged with Galecto in January 2020; the combined entity continues development under the Galecto name.
- Therapeutic areas
- PulmonologyOncologyGastroenterology
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Celgene
Beyond the preview
Go deeper on PharmAkea Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmAkea Therapeutics.